Nova vs MEDVi
A mandatory fee counted inside the price against one that is not named at all.
Nova
Editorial
$139/mo
Two injection lines quoted as all-in figures that already contain a required care fee: $198 for semaglutide and $210 for tirzepatide, with shipping stated as included. A required fee named inside the price is a different proposition from one a buyer meets at checkout. The oral lines are quoted lower, at $156 and $174, but the oral semaglutide bills its first three months together at $269. Coverage is two states.
Pick it for: Buyers who want every mandatory charge inside one number
MEDVi
Editorial
$249/mo
One line priced as a price and two priced as a membership. Compounded semaglutide by injection is a flat $249 with no introductory discount shown, while the oral semaglutide and tirzepatide lines publish $99 as a membership fee and state the medication cost separately without naming it. Coverage is stated across 48 states.
Pick it for: Buyers outside Texas and Florida, where Nova cannot ship
Our verdict
Nova states its care charge is already inside the $198 and $210 injection figures. MEDVi's membership lines bill the medication separately and do not publish what it costs.
What actually separates them
Nova and MEDVi state different things about published price and where you can use it. Everything else they publish, they publish the same way.
MEDVi costs $110 more than Nova — 79% more for the same molecule. Whether that buys anything is what the rest of this page is for.
Over twelve months that is about $1,668 at Nova against $2,988 at MEDVi — a difference of $1,320.
| Nova | MEDVi | |
|---|---|---|
| Published price | $139/mo | $249/mo |
| Where you can use it | 2 states | 48 states |
Before you choose either
Ask both sellers what dose the monthly price buys before you compare the two figures. A price is only a price once you know what quantity it is attached to, and a seller that will not answer has told you something. Set both against every published price we hold rather than against each other alone.
Our take is computed from a published rubric that does not read commercial status, and what is known about safety applies to both of them equally.